tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Virpax Pharmaceuticals Faces Nasdaq Delisting Notice and Leadership Changes

Story Highlights
Virpax Pharmaceuticals Faces Nasdaq Delisting Notice and Leadership Changes

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Virpax Pharmaceuticals ( (VRPX) ) has provided an update.

On April 2, 2025, Virpax Pharmaceuticals received a delisting notice from the Nasdaq Hearings Panel due to non-compliance with the minimum stockholders’ equity requirement. The company’s stock trading will be suspended on April 4, 2025, with delisting finalized after the appeal period. Additionally, on the same day, several board members and the CFO resigned, with no disagreements cited as the cause.

More about Virpax Pharmaceuticals

YTD Price Performance: -87.16%

Average Trading Volume: 364,334

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.59M

Learn more about VRPX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1